Articles | EuroIntervention

Clinical research

10.4244/EIJ-D-22-00475 • Apr 3, 2023

Validation of the Academic Research Consortium High Bleeding Risk (ARC-HBR) criteria in patients undergoing peripheral endovascular interventions

Tomoi Y, Kuramitsu S, Shinozaki T, Soga Y, Kodama K, Imada K, Hiramori S, Ando K

free

Clinical research

10.4244/EIJ-D-22-00609 • Apr 3, 2023

Long-term outcomes of peripheral atherectomy for femoropopliteal endovascular interventions

Krawisz A, Raja A, Jones WS, Schneider P, Shen C, Schermerhorn M, Secemsky E

free

Letter to the editor

10.4244/EIJ-D-22-00838 • Apr 3, 2023

Letter: What is the Carlino technique?

Carlino M, Azzalini L

free

Reply to the letter to the editor

10.4244/EIJ-D-22-00879 • Apr 3, 2023

Reply: What is the Carlino technique?

Di Mario C, Mashayekhi K, Garbo R, Pyxaras S, Ciardetti N, Werner G

free

Editorial

Mar 20, 2023

An ESC/EAPCI consensus statement on renal denervation; a debate on the future of transcatheter mitral valve replacement; a mini focus on interventional pharmacology, from P2Y12 inhibitors to evolocumab; impact of non-fatal periprocedural major adverse events on ten-year mortality; pathologic responses to abluminal biodegradable versus circumferential durable polymer-coated DES; and more

Capodanno D

free

Editorial

10.4244/EIJ-E-23-00003 • Mar 20, 2023

Clopidogrel: still king of the ring for elective percutaneous coronary intervention!

Montalescot G, Ferrante A

free

Editorial

10.4244/EIJ-E-23-00005 • Mar 20, 2023

Effects of PCSK9 inhibitors on platelet function

Räber L, Ueki Y

free

Editorial

10.4244/EIJ-E-23-00004 • Mar 20, 2023

Revascularisation, periprocedural events and survival – and the survival of the randomised controlled trial

Lansky AJ, Ahmad Y

free

Editorial

10.4244/EIJ-E-22-00054 • Mar 20, 2023

Periprocedural adverse events after revascularisation: the importance of getting off to a good start

Gaudino M, Dimagli A

free

Debate

10.4244/EIJ-E-22-00044 • Mar 20, 2023

Transcatheter mitral valve replacement will remain a niche therapy: pros and cons

Cohen D, Ludwig S, Piazza N

free

Expert consensus

10.4244/EIJ-D-22-00723 • Mar 20, 2023

Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

Barbato E, Azizi M, Schmieder R, Lauder L, Böhm M, Brouwers S, Bruno RM, Dudek D, Kahan T, Kandzari D, Lüscher T, Parati G, Pathak A, Ribichini F, Schlaich M, Sharp AS, Sudano I, Volpe M, Tsioufis C, Wijns W, Mahfoud F

free

Clinical research

10.4244/EIJ-D-22-00654 • Mar 20, 2023

Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes

Koshy A, Giustino G, Sartori S, Hooda A, Feng Y, Snyder C, Dasgupta S, Kumar K, Krishnamoorthy-Melarcode P, Sweeny J, Khera S, Serrao G, Sharma R, Dangas G, Kini A, Mehran R, Sharma S

free

Clinical research

10.4244/EIJ-D-22-00719 • Mar 20, 2023

Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic cardiovascular disease: a randomised, double-blind, placebo-controlled study

Franchi F, Ortega-Paz L, Rollini F, Been L, Rivas A, Maaliki N, Zhou X, Pineda A, Suryadevara S, Soffer D, Zenni M, Angiolillo D

free

Research correspondence

10.4244/EIJ-D-22-00594 • Mar 20, 2023

Pharmacodynamic effects of cangrelor in elective complex PCI: insights from the POMPEII Registry

Gargiulo G, Marenna A, Sperandeo L, Manzi L, Avvedimento M, Simonetti F, Canonico M, Paolillo R, Spinelli A, Borgia F, Diserafino L, Franzone A, Stabile E, Piccolo R, Cirillo P, Valgimigli M, Esposito G

free

Research correspondence

10.4244/EIJ-D-22-00675 • Mar 20, 2023

Cangrelor for comatose survivors of out-of-hospital cardiac arrest undergoing percutaneous coronary intervention: the CANGRELOR-OHCA study

Kordis P, Bozic Mijovski M, Berden J, Steblovnik K, Blinc A, Noc M

free